SecreTech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SecreTech - overview
Established
2023
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and founded in 2023, SecreTech operates as a biotechnology company that focuses on the development of novel biomarkers and cellular exosomes. In January 2024, the company closed an angel funding led by new investor Shanghai Healthcare Capital, with participation from other new investors Bio Venture, Sinan Yuanke, and Sino-Singapore Suzhou Industrial Park Industrial Investment. SecreTech has developed an antibody affinity-based proteomic detection platform capable of analyzing low-abundance proteomes from plasma and other samples, which solves the current problems in proteomics research and development. Its proprietary Proximity Barcoding Assay (PBA) uses a unique combination of protein molecular tags and RCA neighborhood tags to identify a cluster of proteins.
The services of the company can be used for protein co-localization, qualitative and quantitative analysis of proteins at the level of protein complexes, exosomes and cells.
Current Investors
YuanBio Venture, Shanghai Healthcare Capital, Sino-Singapore Suzhou Industrial Park Industrial Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.